This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Q2 Earnings Season Past the Halfway Mark
by Sheraz Mian
The positive and reassuring view of corporate earnings that we have seen already will likely remain in place.
Bristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View
by Zacks Equity Research
Bristol-Myers (BMY) reports encouraging second-quarter results, beating both earnings and sales estimates.
Corning (GLW) Beats Q2 Earnings Estimates on Strong Revenues
by Zacks Equity Research
Corning's (GLW) second-quarter results benefited from the revenue upside driven by strength in the company's Optical Communications and Specialty Materials business lines.
Is a Beat in the Cards for Pfizer (PFE) in Q2 Earnings?
by Zacks Equity Research
While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger
Key Takeaways from Lilly's (LLY) Q2 Call: Baricitinib, Cancer Pipeline
by Arpita Dutt
Why were Lilly's (LLY) shares down despite the company delivering a "beat and raise" quarter?
Top Analyst Reports for Oracle, Pfizer & Abbott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Pfizer (PFE) and Abbott (ABT).
What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?
by Zacks Equity Research
Merck KGaA???s (MKGAF) Life Science segment is expected to perform well following the approval of Bavencio.
Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs
by Sweta Killa
Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.
What to Expect from Anthem (ANTM) this Earnings Season?
by Zacks Equity Research
Anthem's (ANTM) second-quarter earnings are likely to be supported by robust medical enrollment. However, rising level of SG&A expenses might put pressure on the bottom line.
Centene (CNC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Centene's (CNC) second-quarter earnings are likely to be driven by Health Net buyout. However, surging level of SG&A expenses might put pressure on the bottom line.
Universal Health (UHS) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Universal Health's (UHS) second-quarter earnings are likely to be boosted by solid revenue growth. However, increasing cost of debt might hurt the bottom line.
Merck's Biosimilar Insulin Gets Tentative FDA Approval
by Zacks Equity Research
Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.
AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?
by Zacks Equity Research
AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.
HCA Healthcare (HCA) Q2 Earnings: Will it Beat Estimates?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter earnings are likely to witness equivalent, admission growth and accretion from a number of acquisitions. Commercial business will likely be a dampener.
Can Merck (MRK) Pull Off a Surprise this Earnings Season?
by Zacks Equity Research
Merck & Co., Inc.'s (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q2. However, headwinds remain in the form genericization of key drugs and increasing competition.
What Lies in Store for Glaxo (GSK) this Earnings Season?
by Zacks Equity Research
The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair.
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.
Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
4 Healthcare Megatrends for Investors
by Kevin Cook
One sector combines the best of science and technology with our dreams for healthier and wealthier lives.
J&J (JNJ) Beats on Q2 Earnings, Lags Sales, Ups 2017 View
by Zacks Equity Research
Johnson & Johnson (JNJ) reported mixed second-quarter 2017 results. While earnings beat expectations, sales missed the same.
Paratek Antibiotic Candidate's Phase III Data Favorable
by Zacks Equity Research
Paratek Pharmaceuticals, Inc. (PRTK) announced positive results from a phase III study (OASIS-2) comparing its antibiotic candidate omadacycline to Pfizer Inc.'s (PFE) Zyvox for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Pfizer Xeljanz Label Expansion Application Accepted by FDA
by Zacks Equity Research
Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) for Xeljanz has been accepted for review by the FDA.
Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.
by Arpita Dutt
Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.
Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?
by Zacks Equity Research
Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company's shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized industry during this period.